Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Stoke Therapeutics Inc (STOK)
NASDAQ:STOK
Stoke Therapeutics (STOK) Stock Price & Analysis
306 Followers
STOK Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.35 - $16.40
Previous Close$14.03
Volume471.16K
Average Volume (3M)1.36M
Market Cap
$731.24M
Enterprise Value$552.66M
Total Cash (Recent Filing)$178.58M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-5.8
Beta1.56
Next Earnings
Aug 05, 2024EPS Estimate
-$0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.42
Shares Outstanding52,119,860
10 Day Avg. Volume717,506
30 Day Avg. Volume1,361,732
Standard Deviation0.24
R-Squared0.03
Alpha0.00195
Financial Highlights & Ratios
Price to Book (P/B)4.75
Price to Sales (P/S)173.44
Price to Cash Flow (P/CF)-6.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue70.46
Enterprise Value/Gross Profit62.95
Enterprise Value/Ebitda-6.71
Forecast
1Y Price Target
$22.14Price Target Upside59.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Stoke Therapeutics News
PremiumCompany Announcements
Stoke Therapeutics Launches Public Offering for Clinical Development
Bulls Say, Bears Say
Bulls Say
Drug Development ProgressSTK-001 could become the first disease-modifying therapy for Dravet syndrome, offering hope for patients with this challenging condition.
Financial StabilityFollowing a successful follow-on offering, the company's strong cash position is expected to fund key Phase 3 studies, demonstrating financial readiness for critical research advancements.
Regulatory MilestonesFDA clearance for a new dosing regimen of STK-001 marks a significant step forward, potentially leading to enhanced treatment outcomes for Dravet syndrome patients.
Bears Say
Clinical Trial ConcernsA single patient in the trials of STK-001 discontinued dosing due to elevated protein levels in the CSF; a patient treated with 70 mg experienced a significant adverse event termed a SUSAR.
Price Target AdjustmentTweaking PT from $21 to $20 on higher expense estimates, share count.
Report CredibilityThe report requires a full review with disclaimers, suggesting that the information provided should be considered with caution.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
STOK FAQ
What was Stoke Therapeutics Inc’s price range in the past 12 months?
Stoke Therapeutics Inc lowest stock price was $3.35 and its highest was $16.40 in the past 12 months.
What is Stoke Therapeutics Inc’s market cap?
Currently, no data Available
When is Stoke Therapeutics Inc’s upcoming earnings report date?
Stoke Therapeutics Inc’s upcoming earnings report date is Aug 05, 2024 which is in 79 days.
How were Stoke Therapeutics Inc’s earnings last quarter?
Stoke Therapeutics Inc released its earnings results on May 06, 2024. The company reported -$0.57 earnings per share for the quarter, beating the consensus estimate of -$0.61 by $0.04.
Is Stoke Therapeutics Inc overvalued?
According to Wall Street analysts Stoke Therapeutics Inc’s price is currently Undervalued.
Does Stoke Therapeutics Inc pay dividends?
Stoke Therapeutics Inc does not currently pay dividends.
What is Stoke Therapeutics Inc’s EPS estimate?
Stoke Therapeutics Inc’s EPS estimate is -$0.55.
How many shares outstanding does Stoke Therapeutics Inc have?
Stoke Therapeutics Inc has 52,119,860 shares outstanding.
What happened to Stoke Therapeutics Inc’s price movement after its last earnings report?
Stoke Therapeutics Inc reported an EPS of -$0.57 in its last earnings report, beating expectations of -$0.61. Following the earnings report the stock price went down -1.248%.
Which hedge fund is a major shareholder of Stoke Therapeutics Inc?
Among the largest hedge funds holding Stoke Therapeutics Inc’s share is Baker Bros Advisors LP. It holds Stoke Therapeutics Inc’s shares valued at 11M.
---
Stoke Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.14 (59.28% Upside)
$22.14 (59.28% Upside)
Blogger Sentiment
Bullish
STOK Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 544.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $41.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 2.4%
Last 30 Days ▲ 1.2%
Last 30 Days ▲ 1.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
25.04%
12-Months-Change
Fundamentals
Return on Equity
-61.29%
Trailing 12-Months
Asset Growth
-27.19%
Trailing 12-Months
Company Description
Stoke Therapeutics Inc
Stoke Therapeutics, Inc. engages in the research and development of treatments for genetic diseases. It is a biotechnology firm that focuses to increase gene expression to treat severe genetic diseases, including genetic conditions affecting the central nervous system, eye, ear, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.
---
STOK Stock 12 Month Forecast
Average Price Target
$22.14
▲(59.28% Upside)
Technical Analysis
Best Analysts Covering STOK
1 Year
1 Year Success Rate
8/13 ratings generated profit
1 Year Average Return
+42.25%
reiterated a buy rating 11 days ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 61.54% of your transactions generating a profit, with an average return of +42.25% per trade.
---